Skip to main content
Erschienen in: Current Fungal Infection Reports 3/2016

10.08.2016 | Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Azole Resistance in Moulds—Approach to Detection in a Clinical Laboratory

verfasst von: Anuradha Chowdhary, Aradhana Masih, Cheshta Sharma

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The multitude of factors has contributed to the increasing number of fungal infections caused by species of difficult-to-treat opportunistic moulds, such as Fusarium, Scedosporium, and cryptic Aspergilli. Also, rare fungi sporadically encountered, such as Rasamsonia argillacea, Penicillium oxalicum, and melanized fungi, are now well recognized. The high mortality associated with these rare and uncommon fungi is primarily linked to the difficulty in diagnosis and limited therapeutic options, as many of them exhibit resistance to antifungals including azoles. Azole resistance in Aspergillus fumigatus has been increasingly reported because standardized methods for susceptibility testing and associated clinical breakpoints and epidemiological cutoff values became available. However, such advances in antifungal susceptibility testing (AFST) in non-Aspergillus moulds barring mucorales have been lacking. Notwithstanding the fact that the true incidence of these non-Aspergillus filamentous moulds in clinical settings is hitherto unknown, also data on AFST by standardized methods is largely lacking. Determination of minimum inhibitory concentration (MIC) by reference techniques is the gold standard to detect azole resistance in filamentous fungi. In recent years, some progress has been made toward the description of resistance mechanisms at molecular level especially in Aspergillus. This paper reviews the present state of azole resistance in Aspergillus and other filamentous mould species and discusses their relevance to clinical practice.
Literatur
1.
Zurück zum Zitat Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367:2214–25.CrossRefPubMed Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367:2214–25.CrossRefPubMed
3.••
Zurück zum Zitat Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9:e1003633. Highlights the role of fungicides in emergence of azole resistance in A. fumigatus strains. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9:e1003633. Highlights the role of fungicides in emergence of azole resistance in A. fumigatus strains.
4.
Zurück zum Zitat Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.CrossRefPubMed Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.CrossRefPubMed
5.
Zurück zum Zitat Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65:453–64.CrossRefPubMed Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65:453–64.CrossRefPubMed
6.
Zurück zum Zitat Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54:S35–43.CrossRefPubMed Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54:S35–43.CrossRefPubMed
8.
Zurück zum Zitat Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.CrossRefPubMedPubMedCentral Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Doyon JB, Sutton DA, Theodore P, Dhillon G, Jones KD, Thompson EH, et al. Rasamsonia argillacea pulmonary and aortic graft infection in an immune-competent patient. J Clin Microbiol. 2013;51:719–22.CrossRefPubMedPubMedCentral Doyon JB, Sutton DA, Theodore P, Dhillon G, Jones KD, Thompson EH, et al. Rasamsonia argillacea pulmonary and aortic graft infection in an immune-competent patient. J Clin Microbiol. 2013;51:719–22.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Chowdhary A, Kathuria S, Agarwal K, Sachdeva N, Singh PK, Jain S et al, Voriconazole resistant Penicillium oxalicum: an emerging pathogen in immunocompromised hosts. Open Forum Infect Dis. 2014; doi:10.1093/ofid/ofu029 Chowdhary A, Kathuria S, Agarwal K, Sachdeva N, Singh PK, Jain S et al, Voriconazole resistant Penicillium oxalicum: an emerging pathogen in immunocompromised hosts. Open Forum Infect Dis. 2014; doi:10.​1093/​ofid/​ofu029
11.
Zurück zum Zitat Singh PK, Kathuria S, Agarwal K, Gaur SN, Meis JF, Chowdhary A. Clinical significance and molecular characterization of nonsporulating molds isolated from the respiratory tracts of bronchopulmonary mycosis patients with special reference to basidiomycetes. J Clin Microbiol. 2013;51:3331–7.CrossRefPubMedPubMedCentral Singh PK, Kathuria S, Agarwal K, Gaur SN, Meis JF, Chowdhary A. Clinical significance and molecular characterization of nonsporulating molds isolated from the respiratory tracts of bronchopulmonary mycosis patients with special reference to basidiomycetes. J Clin Microbiol. 2013;51:3331–7.CrossRefPubMedPubMedCentral
12.••
Zurück zum Zitat Sleiman S, Halliday CL, Chapman B, Brown M, Nitschke J, Lau AF, et al. Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of Aspergillus, Scedosporium, and Fusarium spp. in the Australian clinical setting. J Clin Microbiol. 2016. A database was prepared for the identification of Aspergillus, Scedosporium , and Fusarium species using MALDI-TOF MS by combining in-house database with Bruker Fungal library, thereby improving the species identification significantly. Sleiman S, Halliday CL, Chapman B, Brown M, Nitschke J, Lau AF, et al. Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of Aspergillus, Scedosporium, and Fusarium spp. in the Australian clinical setting. J Clin Microbiol. 2016. A database was prepared for the identification of Aspergillus, Scedosporium , and Fusarium species using MALDI-TOF MS by combining in-house database with Bruker Fungal library, thereby improving the species identification significantly.
13.
Zurück zum Zitat Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 2014;4 Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 2014;4
14.
Zurück zum Zitat Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.CrossRefPubMed Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.CrossRefPubMed
15.
Zurück zum Zitat Peterson SW. Phylogenetic analysis of Aspergillus species using DNA sequences from four loci. Mycologia. 2008;100:205–26.CrossRefPubMed Peterson SW. Phylogenetic analysis of Aspergillus species using DNA sequences from four loci. Mycologia. 2008;100:205–26.CrossRefPubMed
16.
Zurück zum Zitat Balajee SA, Baddley JW, Peterson SW, Nickle D, Varga J, Boey A, et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell. 2009;8:713–22.CrossRefPubMedPubMedCentral Balajee SA, Baddley JW, Peterson SW, Nickle D, Varga J, Boey A, et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell. 2009;8:713–22.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3138–41.CrossRefPubMedPubMedCentral Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3138–41.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Alastruey-Izquierdo A, Mellado E, Peláez T, Pemán J, Zapico S, Alvarez M, et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother. 2013;57:3380–7.CrossRefPubMedPubMedCentral Alastruey-Izquierdo A, Mellado E, Peláez T, Pemán J, Zapico S, Alvarez M, et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother. 2013;57:3380–7.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52:1244–51.CrossRefPubMedPubMedCentral Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52:1244–51.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M. Antifungal susceptibility profile of cryptic species of Aspergillus. Mycopathologia. 2014;178:427–33.CrossRefPubMed Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M. Antifungal susceptibility profile of cryptic species of Aspergillus. Mycopathologia. 2014;178:427–33.CrossRefPubMed
21.
Zurück zum Zitat Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45–68.CrossRefPubMed Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45–68.CrossRefPubMed
22.
Zurück zum Zitat Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016.
23.
Zurück zum Zitat Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–9.CrossRefPubMed Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–9.CrossRefPubMed
24.
Zurück zum Zitat Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Møller N, Khan H, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One. 2010;5:e10080.CrossRefPubMedPubMedCentral Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Møller N, Khan H, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One. 2010;5:e10080.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364–8.PubMedPubMedCentral Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364–8.PubMedPubMedCentral
26.•
Zurück zum Zitat Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. Investigated the prevalence and spread of azole resistance in A. fumigatus isolates collected over a period of 14 years. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. Investigated the prevalence and spread of azole resistance in A. fumigatus isolates collected over a period of 14 years.
27.
Zurück zum Zitat Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116–8.CrossRefPubMed Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116–8.CrossRefPubMed
28.••
Zurück zum Zitat Bader O, Tünnermann J, Dudakova A, Tangwattanachuleeporn M, Weig M, Groß U. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother. 2015;59:4356–9. The article describes that 12 % of the soil samples were positive for resistant A. fumigatus and harbored TR 34 /L98H and TR 46 /Y121F/T289A alleles, dispersed along a corridor across northern Germany. Bader O, Tünnermann J, Dudakova A, Tangwattanachuleeporn M, Weig M, Groß U. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother. 2015;59:4356–9. The article describes that 12 % of the soil samples were positive for resistant A. fumigatus and harbored TR 34 /L98H and TR 46 /Y121F/T289A alleles, dispersed along a corridor across northern Germany.
29.••
Zurück zum Zitat Sharma C, Hagen F, Moroti R, Meis JF, Chowdhary A. Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: is it de novo or environmentally acquired? J Global Antimicrob Resist. 2015;3:69–73. The authors describe the genetic heterogeneity of resistant A. fumigatus strains harboring the G54E mutation in the environment of India, Romania, and Tanzania anticipating that long-term exposure of A. fumigatus to fungicides may induce selection of G54 mutants in the environment. Sharma C, Hagen F, Moroti R, Meis JF, Chowdhary A. Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: is it de novo or environmentally acquired? J Global Antimicrob Resist. 2015;3:69–73. The authors describe the genetic heterogeneity of resistant A. fumigatus strains harboring the G54E mutation in the environment of India, Romania, and Tanzania anticipating that long-term exposure of A. fumigatus to fungicides may induce selection of G54 mutants in the environment.
30.
Zurück zum Zitat Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62:362–8.CrossRefPubMed Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62:362–8.CrossRefPubMed
31.
Zurück zum Zitat Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9:697–711.CrossRefPubMed Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9:697–711.CrossRefPubMed
32.••
Zurück zum Zitat Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425–30. The authors gave an insight into the mutations in the cyp51A gene and correlated the mutations with the phenotype regarding their susceptibility to azole compounds. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425–30. The authors gave an insight into the mutations in the cyp51A gene and correlated the mutations with the phenotype regarding their susceptibility to azole compounds.
33.
Zurück zum Zitat Arabatzis M, Kambouris M, Kyprianou M, Chrysaki A, Foustoukou M, Kanellopoulou M, et al. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrob Agents Chemother. 2011;55:3025–30.CrossRefPubMedPubMedCentral Arabatzis M, Kambouris M, Kyprianou M, Chrysaki A, Foustoukou M, Kanellopoulou M, et al. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrob Agents Chemother. 2011;55:3025–30.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Masih A, Singh PK, Kathuria K, Agarwal K, Meis JF, Chowdhary A. Identification by molecular methods and Matrix-assistedlaser desorption ionization–time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare Aspergillus species in a referral chest hospital in Delhi, India. J Clin Microbiol. 2016, pii: JCM.00962-16. Masih A, Singh PK, Kathuria K, Agarwal K, Meis JF, Chowdhary A. Identification by molecular methods and Matrix-assistedlaser desorption ionization–time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare Aspergillus species in a referral chest hospital in Delhi, India. J Clin Microbiol. 2016, pii: JCM.00962-16.
35.
Zurück zum Zitat Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. Breakpoints for antifungal agents: an update from EUCAST focusing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat. 2013;16:81–95.CrossRefPubMed Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. Breakpoints for antifungal agents: an update from EUCAST focusing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat. 2013;16:81–95.CrossRefPubMed
36.
Zurück zum Zitat Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855–9.CrossRefPubMedPubMedCentral Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855–9.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Flörl C, Martin-Mazuelos E, Meis J, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSIM38-A2 broth microdilution method. Antimicrob Agents Chemother. 2013;57:3823–8.CrossRefPubMedPubMedCentral Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Flörl C, Martin-Mazuelos E, Meis J, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSIM38-A2 broth microdilution method. Antimicrob Agents Chemother. 2013;57:3823–8.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother. 2013;57:5426–31.CrossRefPubMedPubMedCentral Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother. 2013;57:5426–31.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist. 2015;21-22:30–40.CrossRef Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist. 2015;21-22:30–40.CrossRef
40.
Zurück zum Zitat Van der Linden JWM, Arendrup MC, van der Lee HAL, Verweij PE. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Mycoses. 2009;52 Suppl 1:19. Van der Linden JWM, Arendrup MC, van der Lee HAL, Verweij PE. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Mycoses. 2009;52 Suppl 1:19.
41.
Zurück zum Zitat Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9.CrossRefPubMedPubMedCentral Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Zhao Y, Stensvold CR, Perlin DS, Arendrup MC. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases. J Antimicrob Chemother. 2013;68:1497–504.CrossRefPubMedPubMedCentral Zhao Y, Stensvold CR, Perlin DS, Arendrup MC. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases. J Antimicrob Chemother. 2013;68:1497–504.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015;52:868–74.CrossRef Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015;52:868–74.CrossRef
44.
Zurück zum Zitat Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, Verweij PE, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011;48:1062–70.CrossRefPubMed Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, Verweij PE, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011;48:1062–70.CrossRefPubMed
45.
Zurück zum Zitat Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747–50.CrossRefPubMedPubMedCentral Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747–50.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Mellado E, Garcia-Effron G, Alcázar-fouli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897–904.CrossRefPubMedPubMedCentral Mellado E, Garcia-Effron G, Alcázar-fouli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897–904.CrossRefPubMedPubMedCentral
47.•
Zurück zum Zitat van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57:513–20. The article describes the emergence of a new environmental resistance mechanism in A. fumigatus isolates from patients and their environment. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57:513–20. The article describes the emergence of a new environmental resistance mechanism in A. fumigatus isolates from patients and their environment.
48.•
Zurück zum Zitat Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA, et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One. 2012;7:e50034. The article reports a new non-cyp51A-mediated resistance mechanism using whole-genome sequencing in the A. fumigatus. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA, et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One. 2012;7:e50034. The article reports a new non-cyp51A-mediated resistance mechanism using whole-genome sequencing in the A. fumigatus.
49.
Zurück zum Zitat Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother. 2011;55:5113–21. Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother. 2011;55:5113–21.
50.
Zurück zum Zitat Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011;55:4802–9.CrossRefPubMedPubMedCentral Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011;55:4802–9.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Tortorano AM, Prigitano A, Esposto MC, Arsic Arsenijevic V, Kolarovic J, Ivanovic D, et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis. 2014;33:1623–30.CrossRefPubMed Tortorano AM, Prigitano A, Esposto MC, Arsic Arsenijevic V, Kolarovic J, Ivanovic D, et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis. 2014;33:1623–30.CrossRefPubMed
52.
Zurück zum Zitat Al-Hatmi AM, Van Den Ende AH, Stielow JB, Van Diepeningen AD, Seifert KA, Mc Cormick W, et al. Evaluation of two novel barcodes for species recognition of opportunistic pathogens in Fusarium. Fungal Biol. 2016;120:231–45.CrossRefPubMed Al-Hatmi AM, Van Den Ende AH, Stielow JB, Van Diepeningen AD, Seifert KA, Mc Cormick W, et al. Evaluation of two novel barcodes for species recognition of opportunistic pathogens in Fusarium. Fungal Biol. 2016;120:231–45.CrossRefPubMed
53.
Zurück zum Zitat Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1491–500.CrossRefPubMed Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1491–500.CrossRefPubMed
54.
Zurück zum Zitat Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92:305–16.CrossRefPubMedPubMedCentral Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92:305–16.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Scheel CM, Hurst SF, Barreiros G, Akiti T, Nucci M, Balajee SA. Molecular analysis of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis. 2013;13:49.CrossRefPubMedPubMedCentral Scheel CM, Hurst SF, Barreiros G, Akiti T, Nucci M, Balajee SA. Molecular analysis of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis. 2013;13:49.CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat van Diepeningen AD, Al-Hatmi AMS, Brankovics B, de Hoog GS. Taxonomy and clinical spectra of Fusarium species: where do we stand in 2014? Curr Clin Micro Rpt. 2014;1:10–8.CrossRef van Diepeningen AD, Al-Hatmi AMS, Brankovics B, de Hoog GS. Taxonomy and clinical spectra of Fusarium species: where do we stand in 2014? Curr Clin Micro Rpt. 2014;1:10–8.CrossRef
57.
Zurück zum Zitat Garnica M, da Cunha MO, Portugal R, Maiolino A, Colombo AL, Nucci M. Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients. Clin Infect Dis. 2015;60:875–80.CrossRefPubMed Garnica M, da Cunha MO, Portugal R, Maiolino A, Colombo AL, Nucci M. Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients. Clin Infect Dis. 2015;60:875–80.CrossRefPubMed
58.
Zurück zum Zitat Vazquez JA, Miceli MH, Alangade G. Invasive fungal infections in transplant recipients. Ther Adv Infect Dis. 2013;3:85–105. Vazquez JA, Miceli MH, Alangade G. Invasive fungal infections in transplant recipients. Ther Adv Infect Dis. 2013;3:85–105.
59.
Zurück zum Zitat Stempel JM, Hammond SP, Sutton DA, Weiser LM, Marty FM. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis. 2015;2:ofv099.CrossRefPubMedPubMedCentral Stempel JM, Hammond SP, Sutton DA, Weiser LM, Marty FM. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis. 2015;2:ofv099.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015;70:1068–71.PubMed Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015;70:1068–71.PubMed
61.
Zurück zum Zitat Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, et al. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother. 2015;60:1079–84.CrossRefPubMed Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, et al. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother. 2015;60:1079–84.CrossRefPubMed
62.
Zurück zum Zitat Abuhelwa AY, Foster DJR, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral SUBA™-itraconazole and Sporanox® capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59:5681–96.CrossRefPubMedPubMedCentral Abuhelwa AY, Foster DJR, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral SUBA™-itraconazole and Sporanox® capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59:5681–96.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Fan J, Urban M, Parker JE, Brewer HC, Kelly SL, Hammond-Kosack KE, et al. Characterization of the sterol 14α-demethylases of Fusarium graminearum identifies a novel genus specific CYP51 function. New Phytol. 2013;198:821–35.CrossRefPubMed Fan J, Urban M, Parker JE, Brewer HC, Kelly SL, Hammond-Kosack KE, et al. Characterization of the sterol 14α-demethylases of Fusarium graminearum identifies a novel genus specific CYP51 function. New Phytol. 2013;198:821–35.CrossRefPubMed
64.
Zurück zum Zitat Harun A, Gilgado F, Chen SC, Meyer W. Abundance of Pseudallescheria/Scedosporium species in the Australian urban environment suggests a possible source for scedosporiosis including the colonization of airways in cystic fibrosis. Med Mycol. 2010;48:S70–6. Harun A, Gilgado F, Chen SC, Meyer W. Abundance of Pseudallescheria/Scedosporium species in the Australian urban environment suggests a possible source for scedosporiosis including the colonization of airways in cystic fibrosis. Med Mycol. 2010;48:S70–6.
65.
Zurück zum Zitat Subedi S, Chen SCA. Epidemiology of scedosporiosis. Curr Fungal Infect Rep. 2015;9:275–84.CrossRef Subedi S, Chen SCA. Epidemiology of scedosporiosis. Curr Fungal Infect Rep. 2015;9:275–84.CrossRef
66.
Zurück zum Zitat Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766–71.CrossRefPubMed Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766–71.CrossRefPubMed
67.
Zurück zum Zitat Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.CrossRefPubMedPubMedCentral Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2009;15:689–93. Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2009;15:689–93.
69.
Zurück zum Zitat Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359–70.CrossRefPubMed Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359–70.CrossRefPubMed
70.•
Zurück zum Zitat Ramsperger M, Duan S, Sorrell TC, Meyer W, Chen SC-A. The genus Scedosporium and Pseudallescheria: current challenges in laboratory diagnosis. Curr Clin Microbiol Rep. 2014;1:27–36. The review abridges the methods currently used to enable an informed choice of detection and/or identification techniques in the clinical mycology laboratory. Ramsperger M, Duan S, Sorrell TC, Meyer W, Chen SC-A. The genus Scedosporium and Pseudallescheria: current challenges in laboratory diagnosis. Curr Clin Microbiol Rep. 2014;1:27–36. The review abridges the methods currently used to enable an informed choice of detection and/or identification techniques in the clinical mycology laboratory.
71.••
Zurück zum Zitat Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635–42. The article reports species-specific susceptibility patterns of Pseudallescheria boydii and P. apiosperma and found only voriconazole exhibited low MIC values for P. apiosperma and P. boydii. Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635–42. The article reports species-specific susceptibility patterns of Pseudallescheria boydii and P. apiosperma and found only voriconazole exhibited low MIC values for P. apiosperma and P. boydii.
72.
Zurück zum Zitat Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses. 2003;46:233–6.CrossRefPubMed Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses. 2003;46:233–6.CrossRefPubMed
73.
Zurück zum Zitat Machouart M, Garcia-Hermoso D, Rivier A, Hassouni N, Catherinot E, Salmon A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol. 2011;49:1681–3.CrossRefPubMedPubMedCentral Machouart M, Garcia-Hermoso D, Rivier A, Hassouni N, Catherinot E, Salmon A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol. 2011;49:1681–3.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Valentin T, Neumeister P, Pichler M, Rohn A, Koidl C, Haas D, et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant. 2012;47:734–6.CrossRefPubMed Valentin T, Neumeister P, Pichler M, Rohn A, Koidl C, Haas D, et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant. 2012;47:734–6.CrossRefPubMed
75.
Zurück zum Zitat Houbraken J, Spierenburg H, Frisvad JC. Rasamsonia, a new genus comprising thermotolerant and thermophilic Talaromyces and Geosmithia species. Antonie Van Leeuwenhoek. 2012;101:403–21.CrossRefPubMed Houbraken J, Spierenburg H, Frisvad JC. Rasamsonia, a new genus comprising thermotolerant and thermophilic Talaromyces and Geosmithia species. Antonie Van Leeuwenhoek. 2012;101:403–21.CrossRefPubMed
76.
Zurück zum Zitat Houbraken J, Verweij PE, Rijs AJ, Borman AM, Samson RA. Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol. 2010;48:2754–61.CrossRefPubMedPubMedCentral Houbraken J, Verweij PE, Rijs AJ, Borman AM, Samson RA. Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol. 2010;48:2754–61.CrossRefPubMedPubMedCentral
77.
Zurück zum Zitat Cohen-Abbo A, Edwards KM. Multifocal osteomyelitis caused by Paecilomyces variotii in a patient with chronic granulomatous disease. Infection. 1995;23:55–7.CrossRefPubMed Cohen-Abbo A, Edwards KM. Multifocal osteomyelitis caused by Paecilomyces variotii in a patient with chronic granulomatous disease. Infection. 1995;23:55–7.CrossRefPubMed
78.
Zurück zum Zitat Eloy P, Bertrand B, Rombeaux P, Delos M, Trigaux JP. Mycotic sinusitis. Acta Otorhinolaryngol Belg. 1997;51:339–52.PubMed Eloy P, Bertrand B, Rombeaux P, Delos M, Trigaux JP. Mycotic sinusitis. Acta Otorhinolaryngol Belg. 1997;51:339–52.PubMed
79.•
Zurück zum Zitat Salle VE, Lecuyer T, Chouaki F, Lescure X, Smail A, Vaidie A, et al. Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review. J Infect. 2005;51:e93–5. The authors report the first case of P. variotii fungemia along with review of literature suggesting substantial morbidity due to this fungus. Salle VE, Lecuyer T, Chouaki F, Lescure X, Smail A, Vaidie A, et al. Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review. J Infect. 2005;51:e93–5. The authors report the first case of P. variotii fungemia along with review of literature suggesting substantial morbidity due to this fungus.
80.
Zurück zum Zitat De Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 2nd ed. Utrecht, Netherlands/ University Rovira i Virgili, Reus, Spain: Centraalbureau voor Schimmelcultures; 2000. De Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 2nd ed. Utrecht, Netherlands/ University Rovira i Virgili, Reus, Spain: Centraalbureau voor Schimmelcultures; 2000.
81.
Zurück zum Zitat Summerbell RC. Aspergillus, Fusarium, Sporothrix, Piedraia, and their relatives. In: Howard DH, editor. Pathogenic fungi in humans and animals. 2nd ed. New York: Marcel Dekker; 2003. p. 237–498. Summerbell RC. Aspergillus, Fusarium, Sporothrix, Piedraia, and their relatives. In: Howard DH, editor. Pathogenic fungi in humans and animals. 2nd ed. New York: Marcel Dekker; 2003. p. 237–498.
82.••
Zurück zum Zitat Perdomo H, Sutton DA, García D, Fothergill AW, Cano J, Gené J, et al. Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol. 2011;49:243–56. The study identified a large number of clinical isolates belonging to Acremonium species morphologically and confirmed the identifications by internal transcribed spacer region of the rRNA gene sequencing. Perdomo H, Sutton DA, García D, Fothergill AW, Cano J, Gené J, et al. Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol. 2011;49:243–56. The study identified a large number of clinical isolates belonging to Acremonium species morphologically and confirmed the identifications by internal transcribed spacer region of the rRNA gene sequencing.
83.
Zurück zum Zitat Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol. 2011;49:586–90.CrossRefPubMedPubMedCentral Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol. 2011;49:586–90.CrossRefPubMedPubMedCentral
85.••
Zurück zum Zitat Chowdhary A, Perfect J, de Hoog GS. Black molds and melanized yeasts pathogenic to humans. Cold Spring Harb Perspect Med. 2014;5:a019570. A comprehensive review describing melanized fungi involved in human infection.CrossRefPubMed Chowdhary A, Perfect J, de Hoog GS. Black molds and melanized yeasts pathogenic to humans. Cold Spring Harb Perspect Med. 2014;5:a019570. A comprehensive review describing melanized fungi involved in human infection.CrossRefPubMed
86.
Zurück zum Zitat Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20 Suppl 3:47–75.CrossRefPubMed Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20 Suppl 3:47–75.CrossRefPubMed
87.••
Zurück zum Zitat Sitterlé E, Giraud S, Leto J, Bouchara JP, Rougeron A, Morio F, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and accurate identification of Pseudallescheria/Scedosporium species. Clin Microbiol Infect. 2014;20:929–35. The authors investigated the potential of MALDI-TOF MS to discriminate Pseudallescheria/Scedosporium species that cannot be currently identified by morphological examination in the clinical setting by building a reference database library. Sitterlé E, Giraud S, Leto J, Bouchara JP, Rougeron A, Morio F, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and accurate identification of Pseudallescheria/Scedosporium species. Clin Microbiol Infect. 2014;20:929–35. The authors investigated the potential of MALDI-TOF MS to discriminate Pseudallescheria/Scedosporium species that cannot be currently identified by morphological examination in the clinical setting by building a reference database library.
88.
Zurück zum Zitat Escribano P, Peláez T, Muñoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother. 2013;57:2815–20.CrossRefPubMedPubMedCentral Escribano P, Peláez T, Muñoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother. 2013;57:2815–20.CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Peláez T, Alvarez-Pérez S, Mellado E, Serrano D, Valerio M, Blanco JL, et al. Invasive aspergillosis caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with leukaemia. J Med Microbiol. 2013;62:474–8.CrossRefPubMed Peláez T, Alvarez-Pérez S, Mellado E, Serrano D, Valerio M, Blanco JL, et al. Invasive aspergillosis caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with leukaemia. J Med Microbiol. 2013;62:474–8.CrossRefPubMed
90.
Zurück zum Zitat Negri CE, Gonçalves SS, Xafranski H, Bergamasco MD, Aquino VR, Castro PT, et al. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol. 2014;52:3633–40.CrossRefPubMedPubMedCentral Negri CE, Gonçalves SS, Xafranski H, Bergamasco MD, Aquino VR, Castro PT, et al. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol. 2014;52:3633–40.CrossRefPubMedPubMedCentral
91.
Zurück zum Zitat Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol. 2005;43:5996–9. Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol. 2005;43:5996–9.
92.
Zurück zum Zitat Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF, Campbell JW, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis. 2009;49:102–11.CrossRefPubMedPubMedCentral Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF, Campbell JW, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis. 2009;49:102–11.CrossRefPubMedPubMedCentral
93.
Zurück zum Zitat Gonçalves SS, Stchigel AM, Cano J, Guarro J, Colombo AL. In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. Antimicrob Agents Chemother. 2013;57:1944–7. Gonçalves SS, Stchigel AM, Cano J, Guarro J, Colombo AL. In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. Antimicrob Agents Chemother. 2013;57:1944–7.
94.
Zurück zum Zitat Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell. 2008;7:630–8.CrossRefPubMedPubMedCentral Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell. 2008;7:630–8.CrossRefPubMedPubMedCentral
95.
96.
Zurück zum Zitat Arendrup MC, Jensen RH, Grif K, Skov M, Pressler T, Johansen HK, et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis. 2012;206:981–5.CrossRefPubMed Arendrup MC, Jensen RH, Grif K, Skov M, Pressler T, Johansen HK, et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis. 2012;206:981–5.CrossRefPubMed
97.
Zurück zum Zitat Wang H, Xiao M, Kong F, Chen S, Dou HT, Sorrell T, et al. Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. J Clin Microbiol. 2011;49:1890–8.CrossRefPubMedPubMedCentral Wang H, Xiao M, Kong F, Chen S, Dou HT, Sorrell T, et al. Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. J Clin Microbiol. 2011;49:1890–8.CrossRefPubMedPubMedCentral
98.
Zurück zum Zitat Dalyan Cilo B, Al-Hatmi AM, Seyedmousavi S, Rijs AJ, Verweij PE, Ener B, et al. Emergence of fusarioses in a university hospital in Turkey during a 20-year period. Eur J Clin Microbiol Infect Dis. 2015;34:1683–91.CrossRefPubMed Dalyan Cilo B, Al-Hatmi AM, Seyedmousavi S, Rijs AJ, Verweij PE, Ener B, et al. Emergence of fusarioses in a university hospital in Turkey during a 20-year period. Eur J Clin Microbiol Infect Dis. 2015;34:1683–91.CrossRefPubMed
99.
Zurück zum Zitat Ricna D, Lengerova M, Palackova M, Hadrabova M, Kocmanova I, Weinbergerova B, et al. Disseminated fusariosis by Fusarium proliferatum in a patient with aplastic anaemia receiving primary posaconazole prophylaxis—case report and review of the literature. Mycoses. 2016;59:48–55.CrossRefPubMed Ricna D, Lengerova M, Palackova M, Hadrabova M, Kocmanova I, Weinbergerova B, et al. Disseminated fusariosis by Fusarium proliferatum in a patient with aplastic anaemia receiving primary posaconazole prophylaxis—case report and review of the literature. Mycoses. 2016;59:48–55.CrossRefPubMed
100.
Zurück zum Zitat Nishimori M, Takahashi T, Suzuki E, Kodaka T, Hiramoto N, Itoh K, et al. Fatal fungemia with Scedosporium prolificans in a patient with acute myeloid leukemia. Med Mycol J. 2014;55:E63–70.CrossRefPubMed Nishimori M, Takahashi T, Suzuki E, Kodaka T, Hiramoto N, Itoh K, et al. Fatal fungemia with Scedosporium prolificans in a patient with acute myeloid leukemia. Med Mycol J. 2014;55:E63–70.CrossRefPubMed
101.
Zurück zum Zitat Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses. 2011;54 Suppl 3:12–21.CrossRefPubMed Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses. 2011;54 Suppl 3:12–21.CrossRefPubMed
102.
Zurück zum Zitat Homa M, Galgóczy L, Tóth E, Tóth L, Papp T, Chandrasekaran M, et al. In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates. Med Mycol. 2015;5:890–5.CrossRef Homa M, Galgóczy L, Tóth E, Tóth L, Papp T, Chandrasekaran M, et al. In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates. Med Mycol. 2015;5:890–5.CrossRef
103.
Zurück zum Zitat Bernhardt A, Seibold M, Rickerts V, Tintelnot K. Cluster analysis of Scedosporium boydii infections in a single hospital. Int J Med Microbiol. 2015;305:724–8.CrossRefPubMed Bernhardt A, Seibold M, Rickerts V, Tintelnot K. Cluster analysis of Scedosporium boydii infections in a single hospital. Int J Med Microbiol. 2015;305:724–8.CrossRefPubMed
104.
Zurück zum Zitat Júnior MC, de Moraes AA, Silva HM, Costa CR, Silva MR. Acremonium kiliense: case report and review of published studies. Mycopathologia. 2013;176:417–21.CrossRefPubMed Júnior MC, de Moraes AA, Silva HM, Costa CR, Silva MR. Acremonium kiliense: case report and review of published studies. Mycopathologia. 2013;176:417–21.CrossRefPubMed
105.
Zurück zum Zitat Herbrecht R, Letscher-Bru V, Fohrer C, Campos F, Natarajan-Ame S, Zamfir A, et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis. 2002;21:814–7.CrossRefPubMed Herbrecht R, Letscher-Bru V, Fohrer C, Campos F, Natarajan-Ame S, Zamfir A, et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis. 2002;21:814–7.CrossRefPubMed
106.
Zurück zum Zitat Houbraken J, Giraud S, Meijer M, Bertout S, Frisvad JC, Meis JF, et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol. 2013;51:22–30.CrossRefPubMedPubMedCentral Houbraken J, Giraud S, Meijer M, Bertout S, Frisvad JC, Meis JF, et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol. 2013;51:22–30.CrossRefPubMedPubMedCentral
107.
Zurück zum Zitat Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.CrossRefPubMedPubMedCentral Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.CrossRefPubMedPubMedCentral
108.
Zurück zum Zitat De Ravin SS, Challipalli M, Anderson V, Shea YR, Marciano B, Hilligoss D, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis. 2011;52:e136–43.CrossRefPubMedPubMedCentral De Ravin SS, Challipalli M, Anderson V, Shea YR, Marciano B, Hilligoss D, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis. 2011;52:e136–43.CrossRefPubMedPubMedCentral
109.
Zurück zum Zitat da Cunha KC, Sutton DA, Fothergill AW, Gené J, Cano J, Madrid H, et al. In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia. Diagn Microbiol Infect Dis. 2013;76:168–74.CrossRefPubMed da Cunha KC, Sutton DA, Fothergill AW, Gené J, Cano J, Madrid H, et al. In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia. Diagn Microbiol Infect Dis. 2013;76:168–74.CrossRefPubMed
110.
Zurück zum Zitat Giraldo A, Sutton DA, Samerpitak K, de Hoog GS, Wiederhold NP, Guarro J, et al. Occurrence of Ochroconis and Verruconis species in clinical specimens from the United States. J Clin Microbiol. 2014;52:4189–201.CrossRefPubMedPubMedCentral Giraldo A, Sutton DA, Samerpitak K, de Hoog GS, Wiederhold NP, Guarro J, et al. Occurrence of Ochroconis and Verruconis species in clinical specimens from the United States. J Clin Microbiol. 2014;52:4189–201.CrossRefPubMedPubMedCentral
111.
Zurück zum Zitat Badali H, Chander J, Gulati N, Attri A, Chopra R, Najafzadeh MJ, et al. Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi. Med Mycol. 2010;48:763–8.CrossRefPubMed Badali H, Chander J, Gulati N, Attri A, Chopra R, Najafzadeh MJ, et al. Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi. Med Mycol. 2010;48:763–8.CrossRefPubMed
112.
Zurück zum Zitat Cerar D, Malallah YM, Howard SJ, Bowyer P, Denning DW. Isolation, identification and susceptibility of Pyrenochaeta romeroi in a case of eumycetoma of the foot in the UK. Int J Antimicrob Agents. 2009;34:617–8.CrossRefPubMed Cerar D, Malallah YM, Howard SJ, Bowyer P, Denning DW. Isolation, identification and susceptibility of Pyrenochaeta romeroi in a case of eumycetoma of the foot in the UK. Int J Antimicrob Agents. 2009;34:617–8.CrossRefPubMed
113.
Zurück zum Zitat Badali H, Yazdanparast SA, Bonifaz A, Mousavi B, de Hoog GS, Klaassen CH, et al. Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility. Mycopathologia. 2013;175:505–13.CrossRefPubMed Badali H, Yazdanparast SA, Bonifaz A, Mousavi B, de Hoog GS, Klaassen CH, et al. Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility. Mycopathologia. 2013;175:505–13.CrossRefPubMed
114.
Zurück zum Zitat Sang H, Zheng XE, Kong QT, Zhou WQ, He W, Lv GX, et al. A rare complication of ear piercing: a case of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in China. Med Mycol. 2011;49:296–302.CrossRefPubMed Sang H, Zheng XE, Kong QT, Zhou WQ, He W, Lv GX, et al. A rare complication of ear piercing: a case of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in China. Med Mycol. 2011;49:296–302.CrossRefPubMed
Metadaten
Titel
Azole Resistance in Moulds—Approach to Detection in a Clinical Laboratory
verfasst von
Anuradha Chowdhary
Aradhana Masih
Cheshta Sharma
Publikationsdatum
10.08.2016
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 3/2016
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-016-0265-2

Weitere Artikel der Ausgabe 3/2016

Current Fungal Infection Reports 3/2016 Zur Ausgabe

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Review on Tinea Incognita

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Pityriasis Versicolor: Clinical Spectrum and Diagnosis

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Clinical Focus on Malassezia Folliculitis

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Primary and Disseminated Cutaneous Coccidioidomycosis: Clinical Aspects and Diagnosis

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Sporotrichosis in Children: an Update

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Diagnosis of Midwestern Endemic Mycoses

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.